The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BNTC | -5.51% | -76.1% | -24.87% | -100% |
| S&P | +15.37% | +82.64% | +12.79% | +246% |
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firms' proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on November 22, 2019 and is headquartered in Hayward, CA.
No news articles found for Benitec Biopharma.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$118.00K | -29.7% |
| Market Cap | $368.29M | 297.3% |
| Market Cap / Employee | $19.38M | 0.0% |
| Employees | 19 | 18.8% |
| Net Income | -$8,965.00K | -77.2% |
| EBITDA | -$9,685.00K | -69.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $94.59M | 39.3% |
| Accounts Receivable | $7.00K | 75.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $403.00K | 0.0% |
| Short Term Debt | $414.00K | 96.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -41.85% | 1.7% |
| Return On Invested Capital | -941.69% | 8.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3,351.00K | 26.9% |
| Operating Free Cash Flow | -$3,351.00K | 26.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.52 | 4.02 | 3.06 | 3.79 | 92.95% |
| Price to Sales | 136.42 | 1962.22 | - | ||
| Price to Tangible Book Value | 3.52 | 4.02 | 3.06 | 3.79 | 92.95% |
| Enterprise Value to EBITDA | -23.52 | -39.62 | -39.58 | -50.47 | 854.75% |
| Return on Equity | -46.9% | -48.6% | -42.3% | -43.7% | -9.37% |
| Total Debt | $137.00K | $959.00K | $849.00K | $817.00K | 287.20% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
